CO6260078A2 - Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros - Google Patents
Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otrosInfo
- Publication number
- CO6260078A2 CO6260078A2 CO10019664A CO10019664A CO6260078A2 CO 6260078 A2 CO6260078 A2 CO 6260078A2 CO 10019664 A CO10019664 A CO 10019664A CO 10019664 A CO10019664 A CO 10019664A CO 6260078 A2 CO6260078 A2 CO 6260078A2
- Authority
- CO
- Colombia
- Prior art keywords
- post
- traumatic stress
- patient
- disorder
- benzodiazepina
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proveen métodos para tratar un paciente al que se le diagnosticó trastorno por estrés postraumático, para administrar al paciente una cantidad terapéuticamente eficaz de Compuesto A. También se provee métodos para mejorar la capacidad de recuperación en un paciente mediante la administración de una cantidad terapéuticamente eficaz del Compuesto A. También se proveen métodos para diagnosticar trastorno por estrés postraumático en un paciente mediante la administración al paciente de una cantidad terapéuticamente eficaz del Compuesto A y la evaluación de, al menos, uno de: signo, síntoma, o grupo de síntomas del trastorno por estrés postraumático; y el diagnóstico del trastorno por estrés postraumático en el paciente si el Compuesto A reduce al menos uno de: signo, síntoma, y grupo de síntomas del trastorno por estrés postraumático.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93503607P | 2007-07-23 | 2007-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6260078A2 true CO6260078A2 (es) | 2011-03-22 |
Family
ID=40281815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10019664A CO6260078A2 (es) | 2007-07-23 | 2010-02-19 | Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090054403A1 (es) |
EP (1) | EP2182952A4 (es) |
JP (1) | JP2010534676A (es) |
CN (1) | CN101951912A (es) |
AU (1) | AU2008279091A1 (es) |
CA (1) | CA2707858A1 (es) |
CO (1) | CO6260078A2 (es) |
MX (1) | MX2010000937A (es) |
NZ (1) | NZ583193A (es) |
RU (1) | RU2458691C2 (es) |
SG (1) | SG183069A1 (es) |
WO (1) | WO2009015248A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101873799A (zh) * | 2007-07-23 | 2010-10-27 | 辛诺西亚治疗公司 | 用于治疗创伤后应激障碍的4-羟基-4-甲基-哌啶-1-羧酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺 |
SG183696A1 (en) * | 2007-08-06 | 2012-09-27 | Biotie Therapies Inc | Medicaments comprising nepicastat for use in treating dependence on a substance |
AU2016208412A1 (en) * | 2007-08-06 | 2016-08-18 | Biotie Therapies, Inc. | Methods for treating dependence |
EP2501234B1 (en) * | 2009-11-20 | 2017-09-13 | Tonix Pharma Holdings Limited | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
EP2968992B8 (en) | 2013-03-15 | 2020-01-15 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and mannitol |
EP3074525B1 (en) * | 2013-11-26 | 2024-06-26 | University of North Texas Health Science Center at Fort Worth | Personalized medicine approach for treating cognitive loss |
CN107072968B (zh) | 2014-09-18 | 2021-01-12 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐的低共熔混合物配制剂 |
RU2614697C1 (ru) * | 2016-04-12 | 2017-03-28 | Общество с ограниченной ответственностью "Нормофарм" | Нейропротекторное средство |
JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
KR20200015534A (ko) * | 2017-05-30 | 2020-02-12 | 폴 지. 에머슨 | 스트레스 장애에서 호르몬 연쇄반응(hormonal cascade)을 조절하는 조성물 및 방법 |
US11284934B2 (en) * | 2017-07-05 | 2022-03-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating sleep disorders in patients via renal neuromodulation |
CN111479812A (zh) | 2017-12-04 | 2020-07-31 | 巴尔-波特拉及康邦亚股份有限公司 | 多巴胺-b-羟化酶抑制剂 |
EP3723860A1 (en) | 2017-12-11 | 2020-10-21 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
CN109966281B (zh) * | 2019-04-11 | 2021-04-27 | 北京大学 | PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用 |
US20220313647A1 (en) * | 2019-07-25 | 2022-10-06 | Tokyo University Of Science Foundation | Agent for treating, preventing or improving psychiatric and nervous system disorders or symptoms |
WO2024118912A1 (en) * | 2022-11-30 | 2024-06-06 | Blinklab Ltd | Psychopharmacological system and method using eyelid tracking |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
CA2459304A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
EP1336406A1 (en) * | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
CN1662231A (zh) * | 2002-04-24 | 2005-08-31 | 柏树生物科学公司 | 包括应激相关障碍在内的功能性躯体障碍的预防与治疗 |
AU2005215775B2 (en) * | 2004-02-13 | 2011-02-03 | Neuromolecular, Inc. | Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions |
JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び/又は予防用の医薬組成物 |
US20090111817A1 (en) * | 2005-07-06 | 2009-04-30 | Sepracor Inc. | Combinations of Eszopiclone and an Antidepressant |
AU2008229203B2 (en) * | 2007-03-16 | 2014-05-29 | Emory University | Methods and compositions for treatment of drug addiction |
US20090054414A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Rufinamide for the Treatment of Post-Traumatic Stress Disorder |
-
2008
- 2008-07-23 MX MX2010000937A patent/MX2010000937A/es not_active Application Discontinuation
- 2008-07-23 SG SG2012054540A patent/SG183069A1/en unknown
- 2008-07-23 US US12/178,513 patent/US20090054403A1/en not_active Abandoned
- 2008-07-23 WO PCT/US2008/070948 patent/WO2009015248A1/en active Application Filing
- 2008-07-23 JP JP2010518369A patent/JP2010534676A/ja active Pending
- 2008-07-23 AU AU2008279091A patent/AU2008279091A1/en not_active Abandoned
- 2008-07-23 CA CA2707858A patent/CA2707858A1/en not_active Abandoned
- 2008-07-23 RU RU2010106014/15A patent/RU2458691C2/ru not_active IP Right Cessation
- 2008-07-23 EP EP08796518A patent/EP2182952A4/en not_active Withdrawn
- 2008-07-23 CN CN200880108123XA patent/CN101951912A/zh active Pending
- 2008-07-23 NZ NZ583193A patent/NZ583193A/en not_active IP Right Cessation
-
2010
- 2010-02-19 CO CO10019664A patent/CO6260078A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2010534676A (ja) | 2010-11-11 |
CA2707858A1 (en) | 2009-01-29 |
EP2182952A1 (en) | 2010-05-12 |
CN101951912A (zh) | 2011-01-19 |
NZ583193A (en) | 2012-05-25 |
SG183069A1 (en) | 2012-08-30 |
EP2182952A4 (en) | 2010-09-08 |
AU2008279091A1 (en) | 2009-01-29 |
WO2009015248A1 (en) | 2009-01-29 |
MX2010000937A (es) | 2010-06-25 |
US20090054403A1 (en) | 2009-02-26 |
RU2010106014A (ru) | 2011-08-27 |
RU2458691C2 (ru) | 2012-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6260078A2 (es) | Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros | |
CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
UY33700A (es) | ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?. | |
ECSP11011275A (es) | Inhibidor de sglt2 para tratar diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, alteración de la tolerancia a la glucosa e hiperglucemia. | |
AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
DOP2012000155A (es) | Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados | |
EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
CO6220937A2 (es) | Compuestos triciclicos composiciones y procedimientos | |
AR093183A1 (es) | Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras | |
BR112012017073A2 (pt) | Método de tratamento de condições neurológicas com glicosídeos cardíacos | |
EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
WO2007103373A3 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
CO2022002638A2 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
AR063470A1 (es) | Terapia combinada | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
BR112014003704A2 (pt) | moduladores ror gama | |
BR112014009785A8 (pt) | método para tratar ou reduzir efp | |
BR112014003071A2 (pt) | tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical | |
WO2019067405A3 (en) | FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN | |
ECSP13012551A (es) | Terapia de combinación para tratar infección por hcv. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |